A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Poland. Open to participants aged 7 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 21st largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 3rd registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 7 Months to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2007.
This study's enrollment of 355 is close to the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 41st largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 3, and was the 8th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: 28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).
Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: 28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Participants were recruited in Poland from July 2007 to September 2007.
| Milestone | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age |
|---|---|---|---|
| Started | 90 | 112 | 153 |
| Vaccinated dose 1 | 90 | 112 | 152 |
| Vaccinated dose 2 | 90 | 112 | 0 |
| Vaccinated dose 3 | 89 | 0 | 0 |
| Completed | 88 | 112 | 152 |
| Not completed | 2 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age |
|---|---|---|---|
| Common Serotypes - Serotype 4 (n= 84,110,151) | 100.0 (95.7 to 100.0) | 100.0 (96.7 to 100.0) | 99.3 (96.4 to 100.0) |
| Common Serotypes - Serotype 6B (n=83,110,150) | 98.8 (93.5 to 100.0) | 100.0 (96.7 to 100.0) | 99.3 (96.3 to 100.0) |
| Common Serotypes - Serotype 9V (n= 83,104,148) | 98.8 (93.5 to 100.0) | 99.0 (94.8 to 100.0) | 98.6 (95.2 to 99.8) |
| Common Serotypes - Serotype 14 (n= 84,108,135) | 100.0 (95.7 to 100.0) | 100.0 (96.6 to 100.0) | 88.1 (81.5 to 93.1) |
| Common Serotypes - Serotype 18C (n= 83,109,151) | 100.0 (95.7 to 100.0) | 100.0 (96.7 to 100.0) | 98.7 (95.3 to 99.8) |
| Common Serotypes - Serotype 19F (n=84,110,147) | 97.6 (91.7 to 99.7) | 100.0 (96.7 to 100.0) | 98.0 (94.2 to 99.6) |
| Common Serotypes - Serotype 23F (n= 84,110,151) | 98.8 (93.5 to 100.0) | 92.7 (86.2 to 96.8) | 93.4 (88.2 to 96.8) |
| Additional Serotypes - Serotype 1 (n= 83,108,149) | 100.0 (95.7 to 100.0) | 100.0 (96.6 to 100.0) | 96.6 (92.3 to 98.9) |
| Additional Serotypes - Serotype 3 (n= 83,108,149) | 98.8 (93.5 to 100.0) | 100.0 (96.6 to 100.0) | 97.3 (93.3 to 99.3) |
| Additional Serotypes - Serotype 5 (n= 84,107,152) | 97.6 (91.7 to 99.7) | 99.1 (94.9 to 100.0) | 98.7 (95.3 to 99.8) |
| Additional Serotypes - Serotype 6A (n= 84,110,150) | 100.0 (95.7 to 100.0) | 98.2 (93.6 to 99.8) | 100.0 (97.6 to 100.0) |
| Additional Serotypes - Serotype 7F (n= 84,108,142) | 100.0 (95.7 to 100.0) | 100.0 (96.6 to 100.0) | 99.3 (96.1 to 100.0) |
| Additional Serotypes - Serotype 19A (n=84,110,150 | 100.0 (95.7 to 100.0) | 100.0 (96.7 to 100.0) | 100.0 (97.6 to 100.0) |
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 - Dose 1 | 13vPnC Group 2 - Dose 1 | 13vPnC Group 3 - Dose 1 | 13vPnC Group 1 - Dose 2 | 13vPnC Group 2 - Dose 2 | 13vPnC Group 1 - Dose 3 |
|---|---|---|---|---|---|---|
| Tenderness - Any | 15.1 | 33.3 | 42.3 | 15.1 | 43.7 | 15.2 |
| Tenderness - Significant | 1.2 | 0.0 | 4.1 | 3.5 | 4.1 | 6.4 |
| Swelling - Any | 36.0 | 44.5 | 36.9 | 32.2 | 41.0 | 25.0 |
| Swelling - Mild | 32.6 | 36.7 | 28.2 | 28.7 | 36.2 | 20.5 |
| Swelling - Moderate | 11.6 | 24.8 | 20.3 | 14.0 | 12.1 | 11.3 |
| Swelling - Severe | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness - Any | 48.8 | 70.0 | 50.0 | 46.0 | 54.7 | 37.8 |
| Redness - Mild | 41.9 | 55.5 | 37.4 | 40.2 | 44.7 | 31.3 |
| Redness - Moderate | 16.3 | 38.2 | 25.7 | 9.3 | 25.5 | 12.5 |
| Redness - Severe | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Group 1 - Dose 1 | 13vPnC Group 2 - Dose 1 | 13vPnC Group 3 - Dose 1 | 13vPnC Group 1 - Dose 2 | 13vPnC Group 2 - Dose 2 | 13vPnC Group 1 - Dose 3 |
|---|---|---|---|---|---|---|
| Fever ≥38°C but ≤39°C | 3.4 | 3.7 | 0.7 | 8.1 | 5.1 | 5.1 |
| Fever >39°C but ≤40°C | 1.2 | 0.9 | 0.7 | 2.3 | 0.0 | 1.3 |
| Fever >40°C | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Decreased appetite | 19.5 | 22.2 | 16.3 | 17.2 | 25.5 | 17.5 |
| Irritability | 24.1 | 30.6 | 14.3 | 34.5 | 34.0 | 24.7 |
| Increased sleep | 9.2 | 13.0 | 11.6 | 9.3 | 10.1 | 2.6 |
| Decreased sleep | 24.1 | 19.4 | 6.8 | 18.4 | 20.4 | 15.0 |
| Use of antipyretic medication to treat symptoms | 9.2 | 10.1 | 2.7 | 9.3 | 13.3 | 7.6 |
| Use of antipyretic medication to prevent symptoms | 8.0 | 13.8 | 4.8 | 4.7 | 14.3 | 5.1 |
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age |
|---|---|---|---|
| Common Serotypes - Serotype 4 | 3.63 (3.11 to 4.23) | 4.28 (3.78 to 4.86) | 3.37 (2.95 to 3.85) |
| Common Serotypes - Serotype 6B | 4.77 (3.90 to 5.84) | 3.38 (2.81 to 4.06) | 3.41 (2.80 to 4.16) |
| Common Serotypes - Serotype 9V | 2.56 (2.21 to 2.96) | 3.08 (2.69 to 3.53) | 2.67 (2.32 to 3.07) |
| Common Serotypes - Serotype 14 | 8.04 (6.95 to 9.30) | 6.45 (5.48 to 7.59) | 2.24 (1.71 to 2.93) |
| Common Serotypes - Serotype 18C | 2.77 (2.39 to 3.23) | 3.71 (3.29 to 4.19) | 2.56 (2.17 to 3.03) |
| Common Serotypes - Serotype 19F | 2.88 (2.35 to 3.54) | 3.07 (2.68 to 3.51) | 2.53 (2.14 to 2.99) |
| Common Serotypes - Serotype 23F | 2.16 (1.82 to 2.55) | 1.98 (1.64 to 2.39) | 1.55 (1.31 to 1.85) |
| Additional Serotypes - Serotype 1 | 2.88 (2.44 to 3.39) | 2.74 (2.37 to 3.16) | 1.78 (1.52 to 2.08) |
| Additional Serotypes - Serotype 3 | 1.94 (1.68 to 2.24) | 1.86 (1.60 to 2.15) | 1.42 (1.23 to 1.64) |
| Additional Serotypes - Serotype 5 | 2.85 (2.34 to 3.46) | 2.16 (1.89 to 2.47) | 2.33 (2.05 to 2.64) |
| Additional Serotypes - Serotype 6A | 3.72 (3.12 to 4.45) | 2.62 (2.25 to 3.06) | 2.96 (2.52 to 3.47) |
| Additional Serotypes - Serotype 7F | 5.30 (4.54 to 6.18) | 5.99 (5.40 to 6.65) | 4.92 (4.26 to 5.68) |
| Additional Serotypes - Serotype 19A | 4.77 (4.28 to 5.33) | 4.94 (4.31 to 5.65) | 6.03 (5.22 to 6.97) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC 7 to <12 Months of Age | — | 5/90 (5.6%) | 55/90 (61.1%) |
| 13vPnC 12 to <24 Months of Age | — | 2/112 (1.8%) | 77/112 (68.8%) |
| 13vPnC 24 to < 72 Months of Age | — | 2/152 (1.3%) | 74/152 (48.7%) |
| Event | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age |
|---|---|---|---|
| DiarrhoeaGeneral disorders | 1/90 | 0/112 | 0/152 |
| Exanthema subitumInfections and infestations | 1/90 | 0/112 | 0/152 |
| Febrile convulsionNervous system disorders | 1/90 | 0/112 | 0/152 |
| Gastrointestinal infectionInfections and infestations | 1/90 | 0/112 | 0/152 |
| PneumoniaInfections and infestations | 1/90 | 0/112 | 0/152 |
| Thermal burnInjury, poisoning and procedural complications | 1/90 | 0/112 | 0/152 |
| Otitis mediaInfections and infestations | 0/90 | 1/112 | 0/152 |
| PharyngitisInfections and infestations | 0/90 | 1/112 | 1/152 |
| StomatitisGastrointestinal disorders | 0/90 | 1/112 | 0/152 |
| VomitingGastrointestinal disorders | 0/90 | 1/112 | 0/152 |
| Event | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age |
|---|---|---|---|
| Erythema (any)Skin and subcutaneous tissue disorders | 42/86 | 77/110 | 74/148 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 36/86 | 61/110 | 55/147 |
| Erythema (any)Skin and subcutaneous tissue disorders | 40/87 | 58/106 | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 35/87 | 46/103 | — |
| Induration (Any)Skin and subcutaneous tissue disorders | 31/86 | 49/110 | 55/149 |
| Tenderness (any)Skin and subcutaneous tissue disorders | 13/86 | 45/103 | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 13/86 | 36/108 | 63/149 |
| Induration (Any)Skin and subcutaneous tissue disorders | 28/87 | 43/105 | — |
| Erythema (Moderate)Skin and subcutaneous tissue disorders | 14/86 | 42/110 | 38/148 |
| Erythema (any)Skin and subcutaneous tissue disorders | 31/82 | — | — |
| Age Continuous(months) | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age | Total |
|---|---|---|---|---|
| Mean | 8.7 ± 1.6 | 17.6 ± 3.5 | 42.0 ± 13.1 | 25.9 ± 17.0 |
| Sex: Female, Male(Participants) | 13vPnC 7 to <12 Months of Age | 13vPnC 12 to <24 Months of Age | 13vPnC 24 to < 72 Months of Age | Total |
|---|---|---|---|---|
| Female | 47 | 58 | 74 | 179 |
| Male | 43 | 54 | 79 | 176 |
The record gives a start of Jul 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years 5 months after primary completion. A results delay was requested in Jan 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →